Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Nasal Spray for 2 Weeks in Chinese Adult and Adolescent Subjects With Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects can be enrolled when meeting all criteria as below.~  1. Chinese adolescent and adult (male or eligible female) outpatients with the age of \>=12 years~ 2. Confirmative diagnosis of IAR or PER (as definitions from ARIA 2008 and the coming effective Chinese AR management guideline ), by medical history, symptoms, skin prick tests (SPTs)~ 3. Subject must be symptomatic at screening and willing to maintain same environment throughout the study~ 4. Ability to comply with study procedures~ 5. Literate~Exclusion Criteria:~* Subjects should be excluded when meeting one of criteria as below.~  1. Having complications of nasal disease, or vasomotor rhinitis, rhinitis with eosinophilia, or drug rhinitis~ 2. Having complications of bacterial/viral infection of upper respiratory tract~ 3. Having significant systemic diseases~ 4. History of hypersensitivity to steroids and ingredients~ 5. Pregnant women or under lactation~ 6. Patients who started, discontinued or changed dose of desensitization therapy within 30 days before visit 1~ 7. Patients planning to travel outside the region~ 8. Patients judged to be inappropriate by investigators~ 9. Patients who participated in another study within 4 months before screening~ 10. Patients who could not withdraw drugs during screening period or secure withdrawal period until the initiation day of administration, e.g.~      1. allergy medications~     2. other medications that may affect allergic rhinitis or its symptoms~     3. any medications that significantly inhibit CYP3A4, including ritonavir and ketoconazole

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): vehicle placebo nasal spray
- FFNS (Type: EXPERIMENTAL): fluticasone furoate nasal spray

Based on this trial design, predict the completion outcome and termination type (if applicable).